UNASSIGNED: 61 obese men were randomly divided into six groups: Placebo; Tirzepatide 5 mg (T5); Tirzepatide 2.5 mg (T2.5); Hypertrophy, Strength, Power-Circuit Training+Placebo (Ex+P); Hypertrophy, Strength, Power-Circuit Training+Tirzepatide 5 mg (Ex+T5); Hypertrophy, Strength, Power-Circuit Training+Tirzepatide 2.5 mg (Ex+T2.5). All training groups performed aerobic training (AT) after resistance training. Subjects trained for six weeks, three sessions per week. Before and after the intervention period, the participants were evaluated for anthropometric measures, body composition [body weight, body mass index (BMI), waist circumference (WC), waist to hip ratio (WHR) and fat mass (FM)], cardiorespiratory fitness (VO2max), and muscle strength (chest press 1RM and leg press 1RM). Blood biochemistry evaluations included triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), insulin level and insulin resistance (HOMA-IR). To evaluate the differences between the groups, ANCOVA statistical method was used along with Bonferroni\'s post hoc test, and the significance level was P < 0.05.
UNASSIGNED: Body weight, BMI, WC, FM, FBG, LDL-C, TC, TG and HOMA-IR were significantly decreased in Ex+P, Ex+T5 and Ex+T2.5 groups compared to Placebo, T5 and T2.5 groups. WHR significantly decreased in Ex+P, Ex+T5 and Ex+T2.5 groups compared to Placebo group. HDL-C, chest press and leg press significantly increased in Ex+P, Ex+T5 and Ex+T2.5 groups compared to Placebo, T5 and T2.5 groups. VO2max significantly increased and insulin significantly decreased in Ex+P group compared to Placebo, T5 and T2.5 groups. FM, FBG and TG were significantly decreased in both the T2.5 and T5 groups compared to Placebo group. HOMA-IR, LDL-C and TC significantly decreased in the T5 group compared to Placebo group. Also, leg press significantly increased in Ex+P group compared to all other groups.
UNASSIGNED: Performing six weeks of combined resistance and aerobic training in the form of RT+AT alone is more effective than the simultaneous use of Tirzepatide on cardiorespiratory fitness, strength, and modulating insulin levels. Taking Tirzepatide in doses of 5 mg and 2.5 mg in combination with exercise training did not have a significant advantage over exercise training alone. Finally, taking Tirzepatide in doses of 5 mg or 2.5 mg in combination with exercise training is not significantly superior to each other.
■61名肥胖男性随机分为六组:安慰剂;替齐帕肽5mg(T5);替齐帕肽2.5mg(T2.5);肥大,力量,功率电路训练+安慰剂(Ex+P);肥大,力量,动力回路训练+替沙帕肽5mg(Ex+T5);肥大,力量,动力电路训练+替沙帕肽2.5mg(Ex+T2.5)。所有训练组在阻力训练后进行有氧训练(AT)。受试者接受了六周的训练,每周三次。干预期前后,对参与者进行了人体测量评估,身体成分[体重,体重指数(BMI),腰围(WC),腰臀比(WHR)和脂肪量(FM)],心肺健康(VO2max),和肌肉力量(胸部按压1RM和腿部按压1RM)。血液生化评估包括甘油三酯(TG),总胆固醇(TC),低密度脂蛋白胆固醇(LDL-C),高密度脂蛋白胆固醇(HDL-C),空腹血糖(FBG),胰岛素水平和胰岛素抵抗(HOMA-IR)。为了评估组间的差异,ANCOVA统计方法与Bonferroni的事后检验一起使用,显著性水平为P<0.05。
■体重,BMI,WC,FM,FBG,LDL-C,TC,Ex+P组TG和HOMA-IR显著降低,与安慰剂相比,Ex+T5和Ex+T2.5组,T5和T2.5组。Ex+P中WHR显著下降,与安慰剂组相比,Ex+T5和Ex+T2.5组。HDL-C,胸部按压和腿部按压在Ex+P中显著增加,与安慰剂相比,Ex+T5和Ex+T2.5组,T5和T2.5组。与安慰剂相比,Ex+P组的VO2max显著增加,胰岛素显著减少,T5和T2.5组。FM,与安慰剂组相比,T2.5和T5组的FBG和TG均显着降低。HOMA-IR,与安慰剂组相比,T5组的LDL-C和TC显着降低。此外,与所有其他组相比,Ex+P组的腿部按压显着增加。
■单独以RT+AT的形式进行六周的抗阻和有氧训练比同时使用Tirzepatide对心肺健康更有效,力量,调节胰岛素水平。以5mg和2.5mg的剂量服用Tirzepatide与运动训练相结合,与单独的运动训练相比没有显着优势。最后,以5mg或2.5mg的剂量服用Tirzepatide并联合运动训练并无明显优势.